Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Downgraded to “Neutral” at Piper Jaffray Companies
Piper Jaffray Companies lowered shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) from an overweight rating to a neutral rating in a report issued on Monday morning. The brokerage currently has $46.00 target price on the specialty pharmaceutical company’s stock.
Other equities analysts also recently issued reports about the company. Cantor Fitzgerald boosted their price objective on Supernus Pharmaceuticals from $25.00 to $27.00 and gave the company an overweight rating in a research report on Thursday, May 11th. Jefferies Group LLC boosted their price objective on Supernus Pharmaceuticals from $35.00 to $45.00 and gave the company a buy rating in a research report on Wednesday, May 31st. Janney Montgomery Scott began coverage on Supernus Pharmaceuticals in a research report on Friday, July 14th. They issued a neutral rating and a $47.00 price objective on the stock. Cowen and Company boosted their price objective on Supernus Pharmaceuticals from $31.00 to $34.00 and gave the company an outperform rating in a research report on Thursday, May 11th. Finally, Stifel Nicolaus boosted their price objective on Supernus Pharmaceuticals from $30.00 to $36.00 and gave the company a buy rating in a research report on Monday, April 3rd. Three research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $46.14.
Supernus Pharmaceuticals (NASDAQ SUPN) opened at 43.05 on Monday. Supernus Pharmaceuticals has a 12 month low of $17.25 and a 12 month high of $44.95. The stock’s 50 day moving average price is $41.41 and its 200-day moving average price is $32.21. The stock has a market cap of $2.16 billion, a PE ratio of 23.16 and a beta of 1.34.
Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $0.19 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.22 by $0.03. The company had revenue of $57.58 million for the quarter, compared to analysts’ expectations of $57.91 million. Supernus Pharmaceuticals had a net margin of 42.46% and a return on equity of 31.79%. Analysts anticipate that Supernus Pharmaceuticals will post $1.01 EPS for the current fiscal year.
In related news, CFO Gregory S. Patrick sold 54,000 shares of the business’s stock in a transaction that occurred on Monday, April 24th. The stock was sold at an average price of $32.37, for a total value of $1,747,980.00. Following the completion of the sale, the chief financial officer now owns 54,221 shares in the company, valued at $1,755,133.77. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Padmanabh P. Bhatt sold 5,500 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $34.90, for a total value of $191,950.00. Following the completion of the sale, the vice president now owns 43,887 shares of the company’s stock, valued at approximately $1,531,656.30. The disclosure for this sale can be found here. Insiders have sold 90,097 shares of company stock valued at $3,095,503 in the last 90 days. Company insiders own 6.70% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. raised its stake in Supernus Pharmaceuticals by 156,173.3% in the first quarter. BlackRock Inc. now owns 6,696,310 shares of the specialty pharmaceutical company’s stock worth $209,595,000 after buying an additional 6,692,025 shares in the last quarter. AXA bought a new stake in Supernus Pharmaceuticals during the first quarter worth $6,519,000. Vanguard Group Inc. raised its stake in Supernus Pharmaceuticals by 6.6% in the first quarter. Vanguard Group Inc. now owns 2,516,335 shares of the specialty pharmaceutical company’s stock worth $78,762,000 after buying an additional 156,094 shares in the last quarter. Royce & Associates LP acquired a new position in shares of Supernus Pharmaceuticals during the first quarter worth about $4,069,000. Finally, BNP Paribas Arbitrage SA increased its position in shares of Supernus Pharmaceuticals by 1,265.5% in the first quarter. BNP Paribas Arbitrage SA now owns 138,760 shares of the specialty pharmaceutical company’s stock worth $4,343,000 after buying an additional 128,598 shares during the last quarter. Hedge funds and other institutional investors own 90.95% of the company’s stock.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Stock Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.